Researchers find new breast cancer treatment target

August 11, 2014
Researchers find new breast cancer treatment target
IMB's Professor George Muscat with Dr Michael Pearen, Dr Rebecca Fitzsimmons and PhD students Kelvin Tuong and Tae Gyu Oh.

(Medical Xpress)—University of Queensland researchers have discovered a way of predicting cancer-free survival in breast cancer patients and identified a new treatment target.

The researchers, led by Professor George Muscat from UQ's Institute for Molecular Bioscience (IMB), has found that with a particular genetic 'signature' are more likely to survive without their cancer spreading.

Professor Muscat and his team also identified a protein that could be targeted by cancer drugs.

"We examined tissue samples from over 100 breast and discovered that those with low levels of the enzyme PRMT2 had a better chance of surviving without their cancer metastasising," Professor Muscat said.

"This enzyme has the ability to affect hundreds of genes so we also examined these genes and the proteins they produce.

"We identified one of these proteins, RORγ, as a druggable protein, meaning it appears to be a good target for treatment."

Professor Muscat said this discovery suggests in future doctors will be able to more confidently predict outcomes in some breast cancer patients, and subsequently improve treatment regimes.

"It also opens the way to develop a new and novel drug for the treatment of breast cancer."

Professor Muscat and his team are now beginning to examine experimental drugs that target RORγ   to evaluate if any are suitable to decrease the growth of tumours and control metastasis.

Cancer Council Queensland spokesperson Katie Clift said the organisation was proud to fund Professor Muscat's research with a grant of $100,000 for 2014.

"Professor Muscat's research is very promising and we look forward to his findings assisting future treatment of breast cancer, improving survival rates in Queensland.

"Around 2900 Queenslanders are diagnosed with every year, and about 500 people die from the disease.

"Funding local studies is imperative, and we are proud to see such world-class research being undertaken at the University of Queensland."

The discovery, published in scientific journal Molecular Endocrinology, was supported by The University of Queensland and Cancer Council Queensland and used samples and data provided by a National Breast Cancer Foundation Collaborative Research Program.

IMB  acknowledges the contributions of co-authors PhD student Tae Gyu Oh, Dr Peter Bailey, Dr Eloise Dray, Dr Aaron Smith and Dr Dennis Dowhan, and members of the NBCF Collaborative Research Program.

The Institute for Molecular Bioscience, a research institute of The University of Queensland, aims to improve quality of life by advancing medical genomics, drug discovery and biotechnology.

Explore further: Leukaemia gene provides clue to treating triple negative breast cancer

More information: Molecular Endocrinology, press.endocrine.org/doi/abs/10.1210/me.2013-1403

Related Stories

Leukaemia gene provides clue to treating triple negative breast cancer

June 27, 2014
(Medical Xpress)—Cancer Research UK scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast ...

Stopping the spread of breast cancer

June 3, 2014
The primary cause of death from breast cancer is the spread of tumor cells from the breast to other organs in the body. Northwestern Medicine® scientists have discovered a new pathway that can stop breast cancer cells from ...

New clues to aggressive breast cancer

November 12, 2013
(Medical Xpress)—Queensland scientists have identified a genetic "switch" which indicates whether a woman's breast cancer will spread.

Men develop breast cancer, too

July 8, 2014
(HealthDay)—While rare, breast cancer does occur in men and is often diagnosed at a later age and stage than in women, experts say.

Gene marker may predict breast cancer response to tamoxifen

July 22, 2014
(HealthDay)—Researchers have identified genes that may help predict whether a patient with estrogen receptor (ER)-positive breast cancer is likely to benefit from tamoxifen therapy, according to a study published in the ...

Patient navigation may aid in breast cancer treatment in high-risk populations

August 4, 2014
Patient navigation, or the linking of a newly diagnosed cancer patient with a professional trained in assisting patients though the complex journey of cancer diagnosis and treatment, may lead to better breast cancer care ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.